I like the updates, it seems they are trying to bring some interest back to Z to help the share price get closer to a buck and then they will release data on 944 going into P2 to get back over a dollar
944: "Research at Zalicus, presented preclinical data demonstrating that Z944:
• Potently and selectively blocked T-type channel activity
• Exhibited selectivity for the inactivated state and was more active during higher frequency signaling
• Displayed potent activity in preclinical models of pain, particularly inflammatory pain, with efficacy exceeding naproxen"
I like it all.
Z944, a first-in-class T-type calcium channel blocker with enhanced affinity for the inactivated state. Z944 was observed to inhibit currents from the CaV3.1, CaV3.2 and CaV3.3 T-type isoforms with sub-micromolar potencies while maintaining selectivity for the inactivated state over the closed state, and between 260- to 2000-fold selectivity versus other voltage-gated calcium and sodium channels.
Z160 blocked native and recombinant N-type channel currents in an irreversible, dose-dependent manner with sub-micromolar potency and 25- to 100-fold selectivity over P/Q- and L-type calcium channels.